Most popular articles on this site Articles on pharmacy Articles on capitation Articles on disease management

www managedcaremag.com





NOW AVAILABLE
The next generation in online publishing...

Requires
Flash Player 9

Version Test
Download Flash


Sign up to read the digital versions of Managed Care, P&T, and Biotechnology Healthcare. These digital editions are free, searchable, and can be downloaded and read offline. To read a sample of the digital version of Managed Care, follow this link:

Sample digital edition

Register for a free digital subscription

Archive issues of Managed Care:

Supplement to Managed Care:

Ulcerative Colitis: The Value of Persistence in Therapy
Free download
MANAGED CARE December 2007. ©MediMedia USA
News and Commentary

Headlines on Deadline ...

Health insurance for all is essential, but not enough, says the Commonwealth Fund. In the report A High Performance Health System for the United States: An Ambitious Agenda for the Next President, it outlines strategies to contain costs and organize the health care delivery system…. An Ohio House bill may require fully-insured health plans to cover treatment and diagnosis for autism. Many health plans cover the diagnosis, but not the treatment. The proposed bill is modeled on a three-month old health parity law that requires health insurance providers to cover certain psychological conditions…. Combining one well known comparatively low cost synthetic drug with 1 of 6 biologic medications often works best to reduce joint swelling or tenderness, according to a new report funded by the Agency for Healthcare Research and Quality (AHRQ). The report titled, “Comparative Effectiveness of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis in Adults,” concludes that combining methotrexate, a synthetic disease-modifying antirheumatic drug (DMARD), with one of the biologic DMARDs works better than using methotrexate or a biologic DMARD alone. The report also found that methotrexate works as effectively as the biologic DMARDs adalimumab and etanercept for patients who have early-stage rheumatoid arthritis. Adalimumab and etanercept, however, show better short-term results as measured by X-rays of joints.